Breath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: a pilot study

9Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Pulmonary infections caused by mycobacteria cause significant mortality and morbidity in the human population. Diagnosing mycobacterial infections is challenging. An infection can lead to active disease or remain indolent with little clinical consequence. In patients with pulmonary nontuberculosis mycobacteria (PNTM) identification of infection and diagnosis of disease can take months to years. Our previous studies showed the potential diagnostic power of volatile molecules in the exhaled breath samples to detect active pulmonary M. tuberculosis infection. Herein, we demonstrate the ability to detect the disease status of PNTM in the breath of persons with cystic fibrosis (PwCF). We putatively identified 17 volatile molecules that could discriminate between active-NTM disease (n = 6), indolent patients (n = 3), and those patients who have never cultured an NTM (n = 2). The results suggest that further confirmation of the breath biomarkers as a non-invasive and culture-independent tool for diagnosis of NTM disease in a larger cohort of PwCF is warranted

Cite

CITATION STYLE

APA

Mani-Varnosfaderani, A., Gao, A., Poch, K. R., Caceres, S. M., Nick, J. A., & Hill, J. E. (2022). Breath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: a pilot study. Journal of Breath Research, 16(3). https://doi.org/10.1088/1752-7163/ac6bb6

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free